UPDATE: Ironwood Reports Analysis Found that Patients Treated with Lesinurad Plus Allopurinol in CLEAR 1 and CLEAR 2 trials who Continued Treatment in the CLEAR Extension Study, Maintained Target sUA Levels over Full Two Years